CELC · Celcuity Inc.
$92.00
+5.40 (+6.24%)
At close · Aug 14
Market Cap
$4.50B
Shares
48.93M
Celcuity Inc. Earnings Call Transcripts
Every quarterly earnings call for Celcuity Inc. (CELC) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2026-08-13
Celcuity Inc. Q2 FY2026 Earnings Call
Diluted EPS
$-1.44
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-07-14
REVTORPYK FDA Approval Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-10
Goldman Sachs 47th Annual Global Healthcare Conference 2026
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-06-02
Phase 3 VIKTORIA-1 PIK3CA Mutant Cohort Clinical Trial Results Conference Call
Confident tone
Second-line HR+ HER2- advanced breast cancer setting
Forward-looking statements / risk disclosures
Gedatolisib drug profile
Diluted EPS
$-0.97
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Celcuity Inc. Q1 FY2026 Earnings Call
Confident tone
Second-line HR+ HER2- advanced breast cancer setting
Forward-looking statements / risk disclosures
Gedatolisib drug profile
Diluted EPS
$-0.97
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Celcuity Inc. Q4 FY2025 Earnings Call
Confident tone
FDA NDA submission and PDUFA timeline
International regulatory and partnership strategy
Safety and tolerability profile of gedatolisib
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Celcuity Inc. Q3 FY2025 Earnings Call
Confident tone
NDA Submission and FDA Review
VIKTORIA-1 Phase 3 Trial Results
Balance Sheet and Financing
Diluted EPS
$-0.92
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2025-10-20
Phase 3 VIKTORIA-1 HR+/HER2-/PIK3CA WT Trial Results Presentation
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q2
2025-08-14
Celcuity Inc. Q2 FY2025 Earnings Call
Confident tone
VIKTORIA-1 Phase III data
Competitive landscape and positioning
Commercial launch readiness
Diluted EPS
$-1.04
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Celcuity Inc. Q1 FY2025 Earnings Call
Confident tone
Gedatolisib commercial opportunity
VIKTORIA-1 PIK3CA wild-type cohort
Prostate cancer Phase 1b/2 program
Diluted EPS
$-0.86
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Celcuity Inc. Q4 FY2024 Earnings Call
Confident tone
VIKTORIA-1 Phase III trial and upcoming data readouts
Tolerability and safety profile of gedatolisib
VIKTORIA-2 Phase III first-line trial site selection
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Celcuity Inc. Q3 FY2024 Earnings Call
Confident tone
VIKTORIA-1 Phase III Trial Progress
VIKTORIA-2 First-Line Phase III Trial
Breast Cancer Biology and Triplet Regimen Strategy
Diluted EPS
$-0.70
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Celcuity Inc. Q2 FY2024 Earnings Call
Positive tone
VIKTORIA-2 Phase III frontline study launch
VIKTORIA-2 safety run-in design
VIKTORIA-1 PIK3CA wild-type cohort timeline shift
Diluted EPS
$-0.62
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Celcuity Inc. Q1 FY2024 Earnings Call
Confident tone
Patient Population Advantages
VIKTORIA-1 Phase III Trial Progress
Safety Profile
Diluted EPS
$-0.64
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
Celcuity Inc. Q4 FY2023 Earnings Call
Confident tone
Gedatolisib differentiation vs other PAM inhibitors
VIKTORIA-1 Phase 3 trial progress and timeline
Phase 1b gedatolisib + palbociclib + fulvestrant data
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Celcuity Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.83
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Celcuity Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.66
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Celcuity Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.55
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Celcuity Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Celcuity Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.75
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Celcuity Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.67
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Celcuity Inc. Q1 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-23
Celcuity Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Celcuity Inc. Q3 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Celcuity Inc. Q2 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Celcuity Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-16
Celcuity Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Celcuity Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Celcuity Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Celcuity Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Celcuity Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 earnings calls
Key facts
CIK
1603454
CUSIP
15102K100
13F (30d)
265 filings
264 filers
Visit website
Investor relations